Multiple Sclerosis

Philadelphia, PA—Extending the dosing interval of natalizumab to every 6 to 8 weeks may lower the risk for progressive multifocal leukoencephalopathy (PML) without affecting efficacy in patients with multiple sclerosis (MS).
Philadelphia, PA—A systematic literature review conducted by the American Academy of Neurology (AAN) shows that certain forms of medical marijuana can be useful to treat some symptoms of multiple sclerosis (MS), but the evidence is insufficient to support its use in other neurologic diseases, and there are a number of safety concerns with medical marijuana.
Philadelphia, PA—Achieving no evidence of disease activity (NEDA) in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) is a clinically meaningful goal, but a strategy to achieve it remains untested, said Robert Bermel, MD, a neurologist at the Mellen Center for Multiple Sclerosis, the Cleveland Clinic, at the 2014 American Academy of Neurology meeting.
Results of a new study suggest that the rate of peripheral CD4 replenishment after the administration of alemtuzumab, a lymphocyte-depleting anti-CD52 monoclonal antibody, does not correlate with multiple sclerosis (MS) activity in patients with relapsing-remitting MS.
A team of neurologists have proposed a new algorithm to help clinicians determine which patients with relapsing forms of multiple sclerosis (MS) may be suitable for first-line treatment with natalizumab.
New evidence from a phase 2 clinical trial suggests that ofatumumab—a monoclonal antibody used to treat B-cell–related hematologic malignancies—may be beneficial for the treatment of patients with relapsing forms of multiple sclerosis (MS). In this new study, ofatumumab, given twice by infusion 2 weeks apart, was safe and well tolerated in patients with relapsing-remitting MS (RRMS) and reduced the number of new magnetic resonance imaging (MRI) lesions characteristic of the disease.
Lifestyle physical activity should be as central to the health-promoting habits of patients with multiple sclerosis (MS) as exercise training, according to one expert.
Page 3 of 3
Results 21 - 27 of 27
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology